Kidney Fibrosis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Kidney Fibrosis - Pipeline Review, H2 2018’, provides an overview of the Kidney Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis

- The report reviews pipeline therapeutics for Kidney Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Kidney Fibrosis therapeutics and enlists all their major and minor projects

- The report assesses Kidney Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Kidney Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AdAlta Ltd

Angion Biomedica Corp

BiOrion Technologies BV

Cellmid Ltd

Certa Therapeutics Pty Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

GenKyoTex SA

Genzyme ...

AdAlta Ltd

Angion Biomedica Corp

BiOrion Technologies BV

Cellmid Ltd

Certa Therapeutics Pty Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

GenKyoTex SA

Genzyme Corp

iBio Inc

Isarna Therapeutics GmbH

Kadmon Corp LLC

Les Laboratoires Servier SAS

Nash Pharmaceuticals Inc

Novo Nordisk AS

Pharmaxis Ltd

ProMetic Life Sciences Inc

Redx Pharma Plc

Regulus Therapeutics Inc

Scholar Rock Inc

Sirnaomics Inc

Symic Biomedical Inc

Vascular Biogenics Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Kidney Fibrosis - Overview 6

Kidney Fibrosis - Therapeutics Development 7

Kidney Fibrosis - Therapeutics Assessment 15

Kidney Fibrosis ...

Table of Contents

Table of Contents 2

Introduction 5

Kidney Fibrosis - Overview 6

Kidney Fibrosis - Therapeutics Development 7

Kidney Fibrosis - Therapeutics Assessment 15

Kidney Fibrosis - Companies Involved in Therapeutics Development 24

Kidney Fibrosis - Drug Profiles 35

Kidney Fibrosis - Dormant Projects 137

Kidney Fibrosis - Discontinued Products 139

Kidney Fibrosis - Product Development Milestones 140

Appendix 150

List of Tables

List of Tables

Number of Products under Development for Kidney Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Kidney Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Kidney Fibrosis - Pipeline by AdAlta Ltd, H2 2018

Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H2 2018

Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H2 2018

Kidney Fibrosis - Pipeline by Cellmid Ltd, H2 2018

Kidney Fibrosis - Pipeline by Certa Therapeutics Pty Ltd, H2 2018

Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H2 2018

Kidney Fibrosis - Pipeline by Evotec AG, H2 2018

Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2018

Kidney Fibrosis - Pipeline by GenKyoTex SA, H2 2018

Kidney Fibrosis - Pipeline by Genzyme Corp, H2 2018

Kidney Fibrosis - Pipeline by iBio Inc, H2 2018

Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2018

Kidney Fibrosis - Pipeline by Kadmon Corp LLC, H2 2018

Kidney Fibrosis - Pipeline by Les Laboratoires Servier SAS, H2 2018

Kidney Fibrosis - Pipeline by Nash Pharmaceuticals Inc, H2 2018

Kidney Fibrosis - Pipeline by Novo Nordisk AS, H2 2018

Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H2 2018

Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2018

Kidney Fibrosis - Pipeline by Redx Pharma Plc, H2 2018

Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H2 2018

Kidney Fibrosis - Pipeline by Scholar Rock Inc, H2 2018

Kidney Fibrosis - Pipeline by Sirnaomics Inc, H2 2018

Kidney Fibrosis - Pipeline by Symic Biomedical Inc, H2 2018

Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H2 2018

Kidney Fibrosis - Dormant Projects, H2 2018

Kidney Fibrosis - Dormant Projects, H2 2018 (Contd..1), H2 2018

Kidney Fibrosis - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Kidney Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Kidney Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports